<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01880788</url>
  </required_header>
  <id_info>
    <org_study_id>SCMM-AMD-107</org_study_id>
    <nct_id>NCT01880788</nct_id>
  </id_info>
  <brief_title>Genetic Analysis of Chronic Central Serous Chorioretinopathy Masquerading as Neovascular AMD</brief_title>
  <official_title>Evaluation of Genetic Variants in Patients With Type 1 Neovascularization (Sub-retinal Pigment Epithelium Neovascularization) Who Lack Typical Findings of Age Related Macular Degeneration (AMD) But Present With Findings More Consistent With Long-standing Central Serous Chorioretinopathy (CSC).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sequenom, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Vitreous -Retina- Macula Consultants of New York</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sequenom, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will be designed as a case control evaluation to compare the genetic profiles of&#xD;
      three groups of patients categorized according to diagnosis.&#xD;
&#xD;
      Group 1 - CNV secondary to CSC Group 2 - CSC without CNV Group 3 - CNV secondary to advanced&#xD;
      AMD.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To determine if patients presenting with type 1 neovascularization believed to be secondary&#xD;
      to CSC are genetically distinct from typical CSC patients without neovascularization or&#xD;
      patients presenting with choroidal neovascularization (CNV) secondary to advanced AMD.&#xD;
      Disease associated markers detecting variants in ARMS 2, Complement Factor H (CFH) Complement&#xD;
      component 3 (C3), Complement component 2 (C2) , Factor B (FB), VEGFA or other genetic&#xD;
      polymorphisms associated with CNV will be evaluated to determine if the CSC neovascular group&#xD;
      is genetically distinct from the CSC group without neovascularization or the advanced AMD&#xD;
      group.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Actual">August 2015</completion_date>
  <primary_completion_date type="Actual">March 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Total genetic burden</measure>
    <time_frame>Baseline assessment</time_frame>
    <description>The identification of individual genetic markers or a quantitative measure of total genetic burden associated with CNV secondary to CSC vs. CSC vs. CNV secondary to advanced AMD as meaured by the commercially available RetnaGene AMD assay.</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">152</enrollment>
  <condition>Age Related Macular Degeneration</condition>
  <condition>Choroidal Neovascularization</condition>
  <condition>Central Serous Chorioretinopathy</condition>
  <arm_group>
    <arm_group_label>CNV secondary to CSC</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>CSC without CNV</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>CNV secondary to advanced AMD</arm_group_label>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Buccal cells&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients seen for routine visits at the offices of Vitreous Retina Macula Consultants of&#xD;
        New York.&#xD;
&#xD;
        Enrollment will include 150 subjects: 50 will be selected based on diagnosis of CNV&#xD;
        secondary to CSC 50 will be selected based on diagnosis of CSC without neovascularization&#xD;
        and 50 selected based on diagnosis of CNV secondary to advanced AMD.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Caucasian&#xD;
&#xD;
          -  30 years and older (CSC)&#xD;
&#xD;
          -  50 years and older (Advanced AMD)&#xD;
&#xD;
          -  Genders Eligible for Study: Both&#xD;
&#xD;
          -  Completed Consent form&#xD;
&#xD;
          -  Diagnosis of choroidal neovascularization in at least one eye&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient age less than 30 years (CSC).&#xD;
&#xD;
          -  Patient age less than 50 years (AMD).&#xD;
&#xD;
          -  Presence of retinal disease involving the photoreceptors and/or outer retinal layers&#xD;
             other than AMD and CSC such as high myopia, retinal dystrophies, retinal vein&#xD;
             occlusion, diabetic retinopathy and uveitis or similar outer retinal diseases which&#xD;
             have been present prior to the age of 30.&#xD;
&#xD;
          -  Opacities of the ocular media, limitations of pupillary dilation or other problems&#xD;
             sufficient to preclude adequate fundus photography.&#xD;
&#xD;
          -  Missing informed consent&#xD;
&#xD;
          -  Previous sample donation under this protocol&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Vitreous Retina Macula Consultants of New York</name>
      <address>
        <city>New York City</city>
        <state>New York</state>
        <zip>10022</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <study_first_submitted>May 16, 2013</study_first_submitted>
  <study_first_submitted_qc>June 18, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 19, 2013</study_first_posted>
  <last_update_submitted>September 17, 2015</last_update_submitted>
  <last_update_submitted_qc>September 17, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 18, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vitreous -Retina- Macula Consultants of New York</investigator_affiliation>
    <investigator_full_name>K. Bailey Freund, MD</investigator_full_name>
    <investigator_title>Clinical Associate Professor at NYU School of Medicine</investigator_title>
  </responsible_party>
  <keyword>Age Related Macular Degeneration</keyword>
  <keyword>Choroidal Neovascularization</keyword>
  <keyword>Central Serous Chorioretinopathy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Choroidal Neovascularization</mesh_term>
    <mesh_term>Central Serous Chorioretinopathy</mesh_term>
    <mesh_term>Neovascularization, Pathologic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

